100
Participants
Start Date
June 18, 2021
Primary Completion Date
May 5, 2022
Study Completion Date
May 5, 2022
Recombinant two-component COVID-19 vaccine (CHO cell)
The spike (S) protein is the main surface antigen of SARS-CoV-2, mediates entry of SARS CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The RBD interacts with ACE2 and can generate potent neutralizing anti-RBD antibodies.
Placebo
Normal saline (0.9% sodium chloride solution),
Auckland Clinical Studies, Auckland
Christchurch Clinical Studies Trust, Christchurch
Iqvia Pty Ltd
INDUSTRY
Jiangsu Rec-Biotechnology Co., Ltd.
INDUSTRY